To better understand the basis for therapeutic resistance and poor clinical outcomes in PEL, we examined the activation status of key oncogenic and survival signaling pathways, including mTORC1, AKT, PI3K, FOXO, and NF‐κB. This evidence concerns the gene AKT1 and primary effusion lymphoma.